Steris Plc (STE):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Steris Plc (STE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8174
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:38
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Steris Plc (Steris), formerly Steris Ltd is a medical equipment company that provides infection prevention and other procedural products. The company offers products such as OR integration systems, sterilizers, surgical tables and lights, perioperative solutions, endoscopy accessories and barrier solutions. It also provides detergents and skin care products, laboratory testing, linen management and off-site reprocessing, microbial reduction of medical devices, and chemical and biological decontamination technologies for aircraft, buildings, vehicles, and sensitive equipment. Steris offers its products to medical device, healthcare, pharmaceutical, research and laboratory, and defense and industrial markets. The company markets and sells its products through direct sales force, distributors and dealers in the UK and abroad. Steris is headquartered in Derby, the UK.

Steris Plc (STE) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Steris Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Steris Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Steris Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Steris Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Steris Plc, Medical Devices Deals, 2012 to YTD 2018 9
Steris Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Steris Plc, Pharmaceuticals & Healthcare, Deal Details 11
Equity Offering 11
Synergy Health Completes Private Placement Of Shares For USD35 Million 11
Debt Offering 12
Steris Raises USD125 Million in Private Placement of 3.45% Notes Due 2025 12
Steris Raises USD100 Million in Priavte Placement of 3.75% Notes Due 2030 13
Steris Raises USD125 Million in Private Placement of 3.55% Notes Due 2027 14
Steris Raises USD12.5 Million in Private Placement of 4.05% Notes Due 2030 15
Steris Raises USD45 Million in Private Placement of 3.07% Notes Due 2023 16
Steris Raises USD40 Million in Private Placement of 3.85% Notes Due 2025 17
Steris Raises USD45.5 Million in Private Placement of 3.7% Notes Due 2022 18
Steris Raises USD12.5 Million in Private Placement of 4.05% Notes Due 2027 19
Steris Raises USD40 Million in Private Placement of 3.85% Notes Due 2024 20
Acquisition 21
Steris Acquires Synergy Health for USD2.3 Billion 21
Steris Acquires Biotest Labs 23
Steris Plc – Key Competitors 24
Steris Plc – Key Employees 25
Steris Plc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Joint Venture 28
Recent Developments 29
Financial Announcements 29
Aug 08, 2018: STERIS Announces financial results for fiscal 2019 first quarter 29
Feb 07, 2018: STERIS Announces Financial Results for Fiscal 2018 Third Quarter 30
Nov 01, 2017: STERIS Announces Financial Results for Fiscal 2018 Second Quarter 31
Aug 08, 2017: STERIS Announces Financial Results for Fiscal 2018 First Quarter 32
May 09, 2017: STERIS Announces Financial Results for Fiscal 2017 Fourth Quarter and Full Year 33
Feb 07, 2017: STERIS Announces Financial Results for Fiscal 2017 Third Quarter 35
Corporate Communications 37
May 09, 2018: STERIS Announces Changes to Board of Directors 37
Appendix 38
Methodology 38
About GlobalData 38
Contact Us 38
Disclaimer 38

List of Tables
Steris Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Steris Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Steris Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Steris Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Steris Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Steris Plc, Medical Devices Deals, 2012 to YTD 2018 9
Steris Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Synergy Health Completes Private Placement Of Shares For USD35 Million 11
Steris Raises USD125 Million in Private Placement of 3.45% Notes Due 2025 12
Steris Raises USD100 Million in Priavte Placement of 3.75% Notes Due 2030 13
Steris Raises USD125 Million in Private Placement of 3.55% Notes Due 2027 14
Steris Raises USD12.5 Million in Private Placement of 4.05% Notes Due 2030 15
Steris Raises USD45 Million in Private Placement of 3.07% Notes Due 2023 16
Steris Raises USD40 Million in Private Placement of 3.85% Notes Due 2025 17
Steris Raises USD45.5 Million in Private Placement of 3.7% Notes Due 2022 18
Steris Raises USD12.5 Million in Private Placement of 4.05% Notes Due 2027 19
Steris Raises USD40 Million in Private Placement of 3.85% Notes Due 2024 20
Steris Acquires Synergy Health for USD2.3 Billion 21
Steris Acquires Biotest Labs 23
Steris Plc, Key Competitors 24
Steris Plc, Key Employees 25
Steris Plc, Subsidiaries 26
Steris Plc, Joint Venture 28

List of Figures
Steris Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Steris Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Steris Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Steris Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Steris Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Steris Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Steris Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Steris Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Steris Plc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Steris Plc (STE):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Inivata Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Inivata Ltd (Inivata) is a cancer genomics company. The company offers products such as invisionfirst- lungin and visionseq. Its InVisionFirst offers advanced sequencing technology to detect single nucleotide variants copy number variants, insertions and deletions and structural variants in …
  • Top Frontier Investment Holdings Inc:企業の戦略・SWOT・財務分析
    Top Frontier Investment Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Top Frontier Investment Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Numab Innovation AG-製薬・医療分野:企業M&A・提携分析
    Summary Numab Innovation AG (Numab) designs and develops novel therapeutics for the treatment of severe diseases. The company’s lead program ND007, a bispecific antibody fragment which is being evaluated for the treatment of autoimmune diseases. Numab’s other pipeline drug candidates include ND009, …
  • FRESHNESS, CO., LTD:企業の戦略・SWOT・財務情報
    FRESHNESS, CO., LTD - Strategy, SWOT and Corporate Finance Report Summary FRESHNESS, CO., LTD - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Petronet LNG Limited:企業の戦略・SWOT・財務情報
    Petronet LNG Limited - Strategy, SWOT and Corporate Finance Report Summary Petronet LNG Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Monadelphous Group Ltd (MND):企業の財務・戦略的SWOT分析
    Monadelphous Group Ltd (MND) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sumitomo Dainippon Pharma Co Ltd (4506):製薬・医療:M&Aディール及び事業提携情報
    Summary Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, …
  • Public Power Corporation SA (PPC):企業の財務・戦略的SWOT分析
    Public Power Corporation SA (PPC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Talwalkars Better Value Fitness Ltd (TALWALKARS):企業の財務・戦略的SWOT分析
    Talwalkars Better Value Fitness Ltd (TALWALKARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Takara Holdings Inc.:企業の戦略・SWOT・財務分析
    Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary Takara Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tecpetrol SA:企業の戦略的SWOT分析
    Tecpetrol SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Merz Pharma GmbH & Co. KGaA:企業のM&A・事業提携・投資動向
    Merz Pharma GmbH & Co. KGaA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Merz Pharma GmbH & Co. KGaA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Companhia Riograndense de Mineracao:企業の戦略・SWOT・財務情報
    Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report Summary Companhia Riograndense de Mineracao - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • SolaCom Technologies, Inc.:企業の戦略・SWOT・財務情報
    SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report Summary SolaCom Technologies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • LKQ Corporation:企業のM&A・事業提携・投資動向
    LKQ Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's LKQ Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Rostelecom:企業の戦略・SWOT・財務情報
    Rostelecom - Strategy, SWOT and Corporate Finance Report Summary Rostelecom - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Samsung Electronics Co Ltd (005930):電力:M&Aディール及び事業提携情報
    Summary Samsung Electronics Co Ltd (Samsung) is a manufacturer of consumer electronics, information technology and mobile communications, and device solutions. The company’s product portfolio includes television (TV), washing machine, refrigerator, air conditioner, medical devices, monitor, printer, …
  • Kuwait Investment Authority:電力:M&Aディール及び事業提携情報
    Summary The Kuwait Investment Authority (KIA) is an asset management company. It offers fund management and investment management services. The company is responsible for the management and administration of the General Reserve Fund (GRF), apart from the assets of the Future Generations Fund (FGF). …
  • Centogene AG:医療機器:M&Aディール及び事業提携情報
    Summary Centogene AG (Centogene) is a biotechnology and genetic diagnostic company which offers genetic testing for rare hereditary disorders. The company provides diagnostic services including whole genome sequencing, whole exome sequencing, clinical exome sequencing, NGS panel genomic, carrier scr …
  • JBS S.A.:企業のM&A・事業提携・投資動向
    JBS S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's JBS S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆